Theriva™ Biologics, a leading clinical-stage company focused on developing therapies for cancer and related diseases, has announced the participation of its management team in the Investor Summit Virtual scheduled for the first quarter. This event, which will take place on Tuesday, March 11, 2025 at 12:30pm ET, will feature CEO Steve Shallcross and Managing Director, Dr. Manel Cascallo.
During the presentation, Shallcross and Cascallo will provide investors with an update on the company’s most recent advancements and the innovative oncolytic adenovirus platform they have developed. This technology aims to selectively target tumor cells, which could result in a significant improvement in the effectiveness of traditional oncology therapies. The presentation will be broadcast online, allowing a wider audience to follow the updates that Theriva has to offer.
In addition to the presentation, Theriva’s management team will participate in one-on-one meetings with investors, allowing them to delve deeper into the characteristics and potential of their therapeutic candidates. Among the standout projects are VCN-01, an oncolytic adenovirus capable of replicating within tumor cells, SYN-004, which aims to protect the microbiome during antibiotic treatments, and SYN-020, designed to address gastrointestinal diseases.
Theriva Biologics thus reaffirms its commitment to innovation in the field of biology and cancer treatment, offering patients hope in areas where therapeutic need is urgent.
via: MiMub in Spanish
